Wyeth

Genetics Institute, Inc.

Medimmune Limited

Lynette A Fouser

Kenneth A Jacobs

Vikki A Spaulding

Dejun Xuan

Geertruida Machteld Veldman

Jing Li

Ralph Raymond Minter

Debra D Pittman

Davinder Gill

David C Lowe

Viia Valge-Archer

Caroline S Russell

Suzanne E Cohen

Albert George Thom

Margot O'Toole

Deborah P Luxenberg

Martin Hegen

Xiang-Yang Tan

Kathleen N Tomkinson

Wei Liu

Bijia Deng

Viia Valge-archer

Margot O'toole

Davinder S Gill

Margot O' Toole

Albert B Thom

The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22) and methods of using those antibodies, for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.

Methods of using antibodies against human IL-22

The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.

Nucleic acid encoding antibody to human IL-22

Antibodies to human IL-22

Novel human GIL-19/AE289 protein is disclosed which shows a high degree of homology to interleukin-10 (IL-10). Polynucleotides encoding such protein are also enclosed.

Human GIL-19/AE289 proteins

Inhibitors of IL-22 are disclosed as well as pharmaceutical compositions and methods of using same. The inhibitors include IL-22 antibodies and are useful for treating inflammatory disorders.

Method of treating psoriasis by administering IL-22 antibodies, or binding fragments thereof

Antibodies against human IL-22 and uses therefor

Antibodies and antigen-binding fragments thereof that bind interleukin-22 (IL-22), in particular, human IL-22, and their uses in regulating IL-22-associated immune responses are disclosed. The antibodies disclosed herein are useful in diagnosing, preventing, or treating IL-22-associated immune disorders, e.g., autoimmune disorders (e.g., arthritis).

Monoclonal antibodies against interleukin-22

Human GIL-19/AE289 polynucleotides and methods of producing the encoded polypeptides

Human Gil-19/AE289 polynucleotides

Antibodies that bind to interleukin-22

The present invention provides novel isolated CRF2-12 polynucleotides and polypeptides encoded by the CRF2-12 polynucleotides. Also provided are the antibodies that immunospecifically bind to a CRF2-12 polypeptide or any derivative (including fusion derivative), variant, mutant or fragment of the CRF2-12 polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the CRF2-12 polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.

Type 2 cytokine receptor and nucleic acids encoding same

Growing community of inventors

Acton, MA, United States of America

Lynette A Fouser